Detailed guidance on how the UK’s Competition and Markets Authority should evaluate unfair pricing has been provided as part of an appeals court ruling, which largely upholds a previous decision that overturned fines of almost £90m ($112m) imposed by the CMA on Pfizer and its marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.
The fines had previously been rejected by the country’s Competition Appeal Tribunal in a 2018 decision. (Also see "UK...



